GlassScriptPhysician profile
Xavier W Parreno
NPI 1023085479
$37,719.48
in general payments reported to CMS, 2019-2025
53 companies · $5,628 in 2025
The $5,628 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,524 · 2020: $3,921 · 2021: $5,264 · 2022: $5,303 · 2023: $5,260 · 2024: $5,820 · 2025: $5,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $448 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,246.05 |
| Education | $447.95 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,652.33 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $3,258.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,667.10 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $2,631.01 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $2,103.10 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $2,051.65 | 2020-2025 | |
| Corcept Therapeutics | $1,854.71 | 2019-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $1,581.81 | 2019-2024 | |
| Pfizer INC. | $1,449.04 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,287.15 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $1,120.87 | 2019-2025 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,089.73 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Amarin Pharma, INC. | $980.78 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $882.18 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Bayer Healthcare Pharmaceuticals INC. | $817.98 | 2022-2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $748.08 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $719.05 | 2019-2022 | |
| Esperion Therapeutics, INC. | $714.02 | 2021-2025 | Nexletol |
| Astellas Pharma US INC | $565.45 | 2022-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $503.69 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $453.93 | 2020-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $450.87 | 2024-2025 | Voquezna |
| Abbott Laboratories | $448.34 | 2019-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $372.11 | 2023-2025 | Recorlev |
| Allergan, INC. | $359.74 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $338.91 | 2023-2025 | Gemtesa |
| Ardelyx, INC. | $327.95 | 2024-2025 | Ibsrela |
| Kowa Pharmaceuticals America, INC. | $301.86 | 2019-2024 | Livalo |
| Biohaven Pharmaceuticals, INC. | $281.73 | 2021 | |
| Axsome Therapeutics, INC. | $248.70 | 2023 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $225.90 | 2020-2024 | Trintellix |
| Exact Sciences Corporation | $195.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Recordati_rare_diseases_inc. | $164.75 | 2025 | Isturisa |
| Avanir Pharmaceuticals, INC. | $154.66 | 2019 | |
| Sunovion Pharmaceuticals INC. | $119.09 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $98.14 | 2022 | |
| Philips North America LLC | $94.97 | 2019-2023 | |
| Recor Medical INC | $43.49 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Dexcom, INC. | $43.02 | 2024 | Dexcom G6 Transmitter |
| Electromed, INC. | $41.73 | 2022 | |
| Lundbeck LLC | $39.47 | 2023-2025 | Rexulti, Vyepti |
| Radius Health, INC. | $33.59 | 2025 | Tymlos |
| Eisai INC. | $31.94 | 2021-2024 | |
| Impel Pharmaceuticals INC. | $30.35 | 2023 | Trudhesa |
| Regeneron Healthcare Solutions, INC. | $23.76 | 2023 | Evkeeza, Praluent |
| Shire North American Group INC | $18.57 | 2019 | |
| Biogen, INC. | $15.62 | 2024 | Leqembi |
| Urovant Sciences INC | $14.84 | 2022 | |
| Lucid Diagnostics INC. | $14.52 | 2023 | |
| Medtronic Minimed, INC. | $14.30 | 2019 | |
| Medicure Pharma INC. | $14.07 | 2024 | Zypitamag |
| Arbor Pharmaceuticals, INC. | $13.25 | 2019 | |
| Alfasigma USA, INC. | $11.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xavier Parreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.